A Russian patient who received a personalised cancer treatment developed using mRNA technology has completed the full course of therapy, with doctors reporting encouraging results during follow-up examinations.

The first volunteer to undergo the treatment has reportedly remained in good health since completing the therapy, according to information provided by Alexander Gintsburg, scientific director of Moscow’s Gamaleya Research Institute of Epidemiology and Microbiology.

The patient is currently undergoing monthly medical examinations at the National Medical Research Centre for Radiology under Russia’s Ministry of Health. The assessments involve high-resolution computed tomography (CT) scans, which allow specialists to examine his entire body, with particular attention to his lymph nodes.

Gintsburg disclosed that approximately four months have passed since the treatment was completed. He said the patient is reportedly feeling well, while recent medical examinations have detected no evidence of new tumour development.

The patient will remain under medical supervision for another three years to monitor his condition and assess the long-term outcome of the treatment.

Explaining how the vaccine works, Gintsburg said the mRNA-based medication functions by directing the immune system to identify and destroy cancerous cells and metastatic growths.

He noted, however, that the treatment is not a universal cure because cancer tumours differ from one individual to another. Consequently, each vaccine is developed specifically for the patient, taking into account their unique genetic characteristics.

Meanwhile, Kazakhstan is also making progress towards developing its own cancer treatment, known as DVC, with large-scale production expected to commence in mid-2027.

The country’s Minister of Science and Higher Education, Sayasat Nurbek, disclosed that the first phase of clinical testing has been completed, with researchers preparing to proceed to the second stage of trials.